Severe COVID-19 cases (n = 90) | Moderate COVID-19 cases (n = 90) | Healthy controls (n = 180) | Test of sig. | P | |
---|---|---|---|---|---|
Gender | |||||
Male | 34 (37.8%) | 48 (53.3%) | 80 (44.4%) | χ2 = 4.444 | 0.108 |
Female | 56 (62.2%) | 42 (46.7%) | 100 (55.6%) | ||
Age (years) | |||||
Mean ± SD. | 65.46 ± 7.01 | 58.18 ± 17.36 | 61.56 ± 13.02 | F = 14.319* | < 0.001* |
Sig.bet.Grps | P1 < 0.001*,P2 = 0.056,P3 = 0.115 | ||||
Vaccine | |||||
Yes | 4 | 2 | 104 | χ2=125.830 | < 0.001* |
No | 86 | 88 | 76 | ||
WBCs 4.00–11/(mcL) | |||||
Median (IQR) | 10.0 (7.50–13.20) | 10.90 (7.50–14.50) | 8.55 (6.90–9.30) | H = 40.927* | < 0.001* |
Sig.bet.Grps | P1 = 0.685,P2 < 0.001*,P3 < 0.001* | ||||
Platelet 150–400/(mcL) | |||||
Median (IQR) | 205.0 (152.0–249.0) | 231.0 (168.0–311.0) | 313.50 (278.0–364.0) | H = 90.737* | < 0.001* |
Sig.bet.Grps | P1 = 0.030*,P2 < 0.001*,P3 < 0.001* | ||||
HB (g/dl) Male: 14–18 g/dL Female: 12–16 g/dL | |||||
Mean ± SD. | 10.64 ± 1.87 | 11.56 ± 2.13 | 12.89 ± 1.42 | F = 53.898* | < 0.001* |
Sig.bet.Grps | P1 < 0.001*,P2 < 0.001*,P3 < 0.001* | ||||
SGOT (U/L) 8–45 (U/L) | |||||
Median (IQR) | 37.0 (25.0–63.0) | 38.0 (29.0–65.0) | 24.0 (19.0–31.0) | H = 72.280* | < 0.001* |
Sig.bet.Grps | P1 = 0.682,P2 < 0.001*,P3 < 0.001* | ||||
SGPT (U/L) 7–56 (U/L) | |||||
Median (IQR) | 27.0 (18.0–38.0) | 33.0 (21.0–51.0) | 31.0 (23.0–24.0) | H = 6.769* | 0.034* |
P1 = 0.011*,P2 = 0.057,P3 = 0.301 | |||||
BUN (mg/dL) 6–24 mg/dL | |||||
Median (IQR) | 45.0 (22.0–73.0) | 27.0 (18.0–41.0) | 20.0 (17.0–22.0) | H = 91.340* | < 0.001* |
Sig.bet.Grps | P1 = 0.0190*,P2 < 0.001*,P3 < 0.001* | ||||
Creatinine (mg/dL) Male: 0.6-1.2 mg/dL Female: 0.5 to 1.1 mg/dL | |||||
Median (IQR) | 1.30 (0.85–1.94) | 0.90 (0.70–1.50) | 1.00 (0.90–1.10) | H = 22.511* | < 0.001* |
Sig.bet.Grps | P1 < 0.001*,P2 < 0.001*,P3 = 0.808 | ||||
Na+ (mEq/L) 135–145 (mEq/L) | |||||
Mean ± SD. | 140.19 ± 5.45 | 138.09 ± 5.75 | 139.27 ± 2.80 | F = 5.100* | < 0.001* |
Sig.bet.Grps | P1 < 0.001*,P2 = 0.242, P3 = 0.242 | ||||
K+ (mEq/L) 3.5–5.3 (mEq/L) | |||||
Mean ± SD. | 4.45 ± 0.70 | 4.23 ± 0.71 | 4.14 ± 0.53 | F = 7.298* | < 0.001* |
Sig.bet.Grps | P1 = 0.070,P2 < 0.001*,P3 = 0.518 | ||||
TG (mg/dL) Male: 40–160 mg/dL Female: 35–135 mg/dL | |||||
Median (IQR) | 130.0 (109.0–138.0) | 124.0 (104.0–162.0) | 108.0 (102.50–123.0) | H = 41.027* | < 0.001* |
Sig.bet.Grps | P1 = 0.269,P2 < 0.001*,P3 = 0.001* | ||||
Cholesterol (mg/dL) 125–200 mg/dL | |||||
Median (IQR) | 117.0 (94.0–134.0) | 110.0 (98.0–133.0) | 158.50 (149.0–172.0) | H = 182.552* | < 0.001* |
Sig.bet.Grps | P1 = 0.436, P2 < 0.001*,P3 < 0.001* | ||||
HDL (mg/dL) Male: 35–55 mg/dL Female: 45–65 mg/dL | |||||
Median (IQR) | 35.0 (30.0–42.50) | 33.50 (28.0–42.0) | 49.15 (45.80–55.90) | H = 145.707* | < 0.001* |
Sig.bet.Grps | P1 = 0.981, P2 < 0.001*, P3 < 0.001* | ||||
LDL (mg/dL) < 130 mg/dL | |||||
Median (IQR) | 48.0 (38.46–68.40) | 50.40 (37.76–63.0) | 88.0 (77.78–94.60) | H = 161.798* | < 0.001* |
Sig.bet.Grps | P1 = 0.551, P2 < 0.001*, P3 < 0.001* | ||||
PC% | |||||
Mean ± SD. | 73.29 ± 17.8946 | 78.78 ± 16.8114 | 96.51 ± 2.8254 | F = 126.690* | < 0.001* |
Sig.bet.Grps | P1 < 0.001*,P2 < 0.001*,P3 < 0.001* | ||||
INR 0.9–1.1 | |||||
Median (IQR) | 1.20 (1.10–1.40) | 1.16 (1.05–1.30) | 1.03 (1.0–1.06) | H = 125.254* | < 0.001* |
Sig.bet.Grps | P1 = 0.130, P2 < 0.001*, P3 < 0.001* | ||||
CRP (mg/L) < 3 mg/L | |||||
Median (IQR) | 60.0 (24.0–96.0) | 48.0 (17.0–94.0) | 4.50 (2.0–7.0) | H = 194.747* | < 0.001* |
Sig.bet.Grps | P1 = 0.044*,P2 < 0.001*,P3 < 0.001* | ||||
Ferritin (µg/L) Male: 24–336 (µg/L) Female: 11–307 (µg/L) | |||||
Median (IQR) | 445.0 (294.0–700.0) | 420.0 (214.0–657.0) | 93.0 (88.0–100.0) | H = 214.915* | < 0.001* |
Sig.bet.Grps | P1 = 0.030*,P2 < 0.001*,P3 < 0.001* | ||||
D- dimer (µg/mL) 0-0.50 (µg/mL) | |||||
Median (IQR) | 0.94 (0.80–1.54) | 0.81 (0.6–2.20) | 0.20 (0.15–0.23) | H = 243.755* | < 0.001* |
Sig.bet.Grps | P1 = 0.077,P2 < 0.001*,P3 < 0.001* |